Circulating Biomarkers and Disease Activity in Systemic Sclerosis-Associated Interstitial Lung Disease
Issued Date
2023-06-01
Resource Type
ISSN
01252208
Scopus ID
2-s2.0-85164252603
Journal Title
Journal of the Medical Association of Thailand
Volume
106
Issue
6
Start Page
565
End Page
571
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand Vol.106 No.6 (2023) , 565-571
Suggested Citation
Disayabutr S., Raksasagulwong P., Muangchan C., Thiravit P., Wonglaksanapimon S. Circulating Biomarkers and Disease Activity in Systemic Sclerosis-Associated Interstitial Lung Disease. Journal of the Medical Association of Thailand Vol.106 No.6 (2023) , 565-571. 571. doi:10.35755/jmedassocthai.2023.06.13855 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87996
Title
Circulating Biomarkers and Disease Activity in Systemic Sclerosis-Associated Interstitial Lung Disease
Author's Affiliation
Other Contributor(s)
Abstract
Background: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a major cause of death in SSc patients. Several studies have reported that serum anti-Scl-70, Krebs von Lungren-6 (KL-6), and surfactant protein D (SP-D) levels are associated with the presence and progression of ILD in SSc patients. Objective: To examine the correlation between levels of these serum biomarkers and disease severity determined by baseline dyspnea index (BDI), high-resolution computed tomography (HRCT) score, and pulmonary function tests. Materials and Methods: The present study was a single-center, cross-sectional study. Serum anti-Scl-70, KL-6, and SP-D from 20 SSc-ILD patients and five non-ILD subjects were measured. The BDI, HRCT score, and pulmonary function tests were used to assess the severity of ILD in SSc-ILD patients. HRCT abnormalities, including ground-glass opacity (GGO), fibrosis, and honeycombing, were scored by using the semi-quantitative scoring system. Results: Serum anti-Scl-70, KL-6, and SP-D in SSc-ILD patients were significantly higher than those in non-ILD subjects. There was a moderate correlation between diffusing capacity for carbon monoxide (DLCO) and serum KL-6 levels (r=-0.551, p=0.022), while the pulmonary fibrosis (PF) score exhibited a strong correlation with serum KL-6 levels (r=0.630, p=0.003). The PF score had a moderate negative correlation with forced vital capacity (FVC) (r=-0.515, p=0.034) and a strong negative correlation with total lung capacity (TLC) and DLCO (r=-0.625, p=0.007, and r=-0.762, p<0.001, respectively). Conclusion: The levels of serum KL-6, and SP-D are elevated in SSc-ILD patients. Serum KL-6 may be a useful non-invasive biomarker for the disease severity, as determined by DLCO and the extent of fibrosis on HRCT, in patients with SSc-ILD.